Page last updated: 2024-11-05

tiadenol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

tiadenol: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID23403
CHEMBL ID1697775
CHEBI ID135235
SCHEMBL ID153097
MeSH IDM0045693

Synonyms (54)

Synonym
tiadenol [inn:dcf]
bis(hydroxy-ethyl-thio) 1-10 decane [french]
einecs 230-165-6
nsc 66316
2,2'-(1,10-decanediylbis(thio))bisethanol
2,2'-(1,10-decanediylbis(thio))bis-ethanol
ai3-18196
brn 1705474
tiadenolum [inn-latin]
ethanol, 2,2'-(1,10-decanediylbis(thio))bis-
ethanol, 2,2'-(decamethylenedithio)di-
eulip
ll 1558
ethanol,2'-[1,10-decanediylbis(thio)]bis-
nsc-66316
tiaden
1,10-bis(2-hydroxyethylthio)decane
1,10-bis(hydroxyethylthio)decane
2,2'-(decamethylenedithio)diethanol
nsc66316
thiadenol
tiadenol
fonilap
6964-20-1
fonlipol
ethanol,2'-(decamethylenedithio)di-
tiadenol (inn)
D07191
NCIOPEN2_002999
CHEBI:135235
2-[10-(2-hydroxyethylsulfanyl)decylsulfanyl]ethanol
ll-1558
CHEMBL1697775
finlipol
tiaterol
22251270cx ,
tiadenolum
3-01-00-02232 (beilstein handbook reference)
bis(hydroxy-ethyl-thio) 1-10 decane
unii-22251270cx
tiadenol [dcf:inn]
SCHEMBL153097
tiadenol [who-dd]
tiadenol [inn]
tiadenol [mart.]
1,10-bis(.beta.-hydroxyethylthio)decane
tiadenol [mi]
3,14-dithia-1,16-hexadecanediol
DTXSID50219903
2,2'-(decane-1,10-diylbis(sulfanediyl))bis(ethan-1-ol)
DB13348
Q7800043
2-(4-benzyloxy-phenyl)-thiazole-4-carboxylicacidethylester
AKOS040754206

Research Excerpts

Overview

Tiadenol-disulfoxide is a substance with promising hypolipidemic properties. Tiadenol is a hypocholesterolemic drug that inhibits the early steps of cholesterol synthesis.

ExcerptReferenceRelevance
"tiadenol-disulfoxide is a substance with promising hypolipidemic properties; 2."( Experimental studies on pharmacology, metabolism and toxicology with tiadenol-disulfoxide. Dissociation of lipid lowering effects and the induction of peroxisomal and microsomal drug-metabolizing enzymes.
Carini, M; Casciarri, I; Longoni, E; Maffei Facino, R; Tofanetti, O, 1987
)
1.23
"Tiadenol is a hypocholesterolemic drug that inhibits the early steps of cholesterol synthesis. "( The metabolic fate of 14C or 35S labelled tiadenol in rabbit after i.v. and oral administration.
Costermans, J; Desager, JP; Harvengt, C; Sclavons, M,
)
1.84
"Tiadenol-nicotinate is an ester in which two molecules of nicotinic acid are linked to one molecule of tiadenol. "( Antilipolytic activity of tiadenol-nicotinate in isolated fat cells: a comparison with its parent drugs.
Cima, L; Da Re, P; Gaion, RM; Murari, L; Valenti, P, 1985
)
2.01

Bioavailability

ExcerptReferenceRelevance
" Orally administered tiadenol-disulfoxide is well absorbed by the gastrointestinal tract and is eliminated in urine at 45% of the dose in unchanged form, and the remaining being: glucuron-conjugated tiadenol-disulfoxide (10%), S-oxidized metabolites (15%) and sulfoxidized carboxylic metabolites (15%)."( Experimental studies on pharmacology, metabolism and toxicology with tiadenol-disulfoxide. Dissociation of lipid lowering effects and the induction of peroxisomal and microsomal drug-metabolizing enzymes.
Carini, M; Casciarri, I; Longoni, E; Maffei Facino, R; Tofanetti, O, 1987
)
0.83

Dosage Studied

BCMTD was found to be a more potent inducer of peroxisomal beta-oxidation. A dose-response curve of tiadenol showed that carnitine palmitoyltransferase and palmitOYl-CoA synthetase activities rose at low doses.

ExcerptRelevanceReference
" In a separate dose-response study BCMTD was found to be a more potent inducer of peroxisomal beta-oxidation compared to tiadenol."( The hypolipidemic peroxisome-proliferating drug, bis(carboxymethylthio)-1.10 decane, a dicarboxylic metabolite of tiadenol, is activated to an acylcoenzyme A thioester.
Aarsaether, N; Aarsland, A; Berge, RK; Bremer, J, 1990
)
0.7
" A dose-response curve of tiadenol showed that carnitine palmitoyltransferase and palmitoyl-CoA synthetase activities and the ratio of long-chain acyl-CoA to free CoASH in total homogenate rose at low doses before detectable changes occurred in the peroxisomal beta-oxidation and palmitoyl-CoA hydrolase activity."( Correlation between the cellular level of long-chain acyl-CoA, peroxisomal beta-oxidation, and palmitoyl-CoA hydrolase activity in rat liver. Are the two enzyme systems regulated by a substrate-induced mechanism?
Aarsland, A; Berge, RK, 1985
)
0.57
" Since high doses of many hypolipidemic drugs produce hepatic tumors and peroxisomal proliferation in rodents and since no increase in peroxisomes is found in human liver after therapeutic use of lower doses, the dose-response relationship is of interest for the evaluation of the toxicology of this class of agents."( Enzymatic changes in rat liver associated with low and high doses of a peroxisome proliferator.
Aarsland, A; Bakke, OM; Berge, RK; Farstad, M; Hosøy, LH, 1984
)
0.27
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
aliphatic sulfide
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (3)

Assay IDTitleYearJournalArticle
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (63)

TimeframeStudies, This Drug (%)All Drugs %
pre-199053 (84.13)18.7374
1990's8 (12.70)18.2507
2000's1 (1.59)29.6817
2010's1 (1.59)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 18.96

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index18.96 (24.57)
Research Supply Index4.32 (2.92)
Research Growth Index3.98 (4.65)
Search Engine Demand Index18.60 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (18.96)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials5 (7.25%)5.53%
Reviews1 (1.45%)6.00%
Case Studies1 (1.45%)4.05%
Observational0 (0.00%)0.25%
Other62 (89.86%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]